Items tagged with Treatment
CDC: Updated guidelines on managing drug interactions in the treatment of HIV-related tuberculosis (post)
Guidelines for managing pharmacologic interactions that can result when patients receive antiretroviral drugs for treatment of human immunodeficiency virus (HIV) infection together with rifamycin antibiotics for treatment of tuberculosis (TB) have been published previously (1–4). Newly updated guidelines, developed by CDC in collaboration with experts from other key national and international institutions, are now available at http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm.
Better late than never: Efavirenz dose optimization (post)
After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles
Nigeria: Global Fund tasks FG over increasing cases of untreated MDR-TB (post)
The Global Fund, a key partner in the National Tuberculosis and Leprosy Control Programme, NTBLCP, has raised alarm over the increasing cases of untreated multidrug-resistant tuberculosis, MDR-TB, in Nigeria.
TB Alliance grants Fosun Pharma rights to develop, market promising TB cure in China (post)
TB Alliance, an international non-profit drug development organization that develops better, faster-acting, and affordable tuberculosis (TB) drugs, has announced that it is collaborating with, and has granted an exclusive license to, the Shanghai Fosun Pharmaceutical Development Co., Ltd., and its subsidiary Shenyang Hongqi Pharmaceutical Co., Ltd. (Fosun Pharma), to develop and commercialize the first-ever regimen designed to treat both drug-sensitive TB (DS-TB) and multi-drug resistant TB (MDR-TB) for use within People’s Republic of China, Taiwan, Hong Kong and Macau (Licensed Territory).
PaMZ drug combination: a game changer for TB and MDR-TB treatment (post)
A novel drug combination (PaMZ) designed to treat both drug-sensitive and MDR-TB, including those who are HIV positive, is advancing to the crucial Phase III human clinical trial. If all goes well, the three-drug combination therapy will be a game changer for tuberculosis treatment. Among other things, the less toxic regimen cuts down the duration of MDR-TB treatment from 18-24 months to six months, and reduces the number of pills by 97 per cent. MDR-TB treatment is likely to be 90 per cent cheaper.
TB drug approvals, distribution deal inches options forward, but MDR-TB treatment access still uncertain where needed most (post)
Last week’s developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility. That good news for multidrug-resistant TB patients, many of whom have run out of other options, was thanks to an agreement signed by drug maker Janssen and GDF procurement agent Strichting International Dispensary Association. It will make the drug, which is marketed as Sirturo, available to national TB programs and to private providers with treatment programs approved by national programs. Bedaquiline, the first new anti-tuberculosis medicine to win U.S. Food and Drug Administration approval in four decades also received approval from the European Medicines Agency the month before.
India: Dosage of key drug for HIV+ too low to counter TB, reveals study (post)
CHENNAI: Experts may fret about overprescription of drugs for tuberculosis, but it has emerged that central health authorities' mandatory dosage of a key drug for HIV-infected patients with the disease is too low for it to be effective.
Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? (post)
Summary
Dosing of raltegravir when given with rifampicin (post)
WHO (1) recommends that, in resource-limited settings, a first-line antiretroviral treatment (ART) regimen should contain two nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor (preferably efavirenz in patients on concomitant tuberculosis treatment). Partly because of cost considerations, raltegravir is not included as a first-line option in WHO guidelines and is not widely used in resource-limited settings. In high-income settings, raltegravir is included as an option for first-line regimens (2). Even in resource-limited settings, raltegravir is an attractive option for patients who cannot tolerate efavirenz, and if its price could be reduced it might be used more widely.
Armenia: Tackling drug-resistant TB (post)
"I thought I would definitely die, I lost all hope", says Arman, a thirtyfive year-old ex-soldier from Armenia.
Page 4 of 108 · Total posts: 0
←First 3 4 5 Last→